BlinkLab (ASX:BB1) said the Rush University Medical Center in Illinois joined the US Food and Drug 510(k) registrational trial of its smartphone-based digital diagnostic test, BlinkLab Dx 1, according to a Thursday Australian bourse filing.
The pivotal study will enroll around 528 children between the ages of two and 11 years across eight leading US sites.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.